• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

ZAN 300 CO-Diffusion

, Medizintechnik, nSpire Health GmbH

. - Physiologie: Die exakte Bestimmung der Diffusions-Eigenschaften der Lunge ist ein wichtiges Glied der respiratorischen Funktionsanalyse....

KoKo Moe™ und DCII™

, Medizintechnik, nSpire Health GmbH

KoKo Moe™ und DCII™ Filter verbessern die Qualität durch Reduktion des Risikos von Kreuzkontaminationen­. Gleichzeitig wird die Produktivität...

Lophius Biosciences Launches T-Track® ImmunoScan Kit and T-activated® ImmunoScan Cocktail for Monitoring Immune Function in Immunosuppressed Patients

, Medizintechnik, Lophius Biosciences GmbH

Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based research tools...

Disclaimer